GlassScriptPhysician profile
Marcy A Scheurer
NPI 1669922787
$4,508.94
in general payments reported to CMS, 2019-2025
31 companies · $3,004 in 2025
The $3,004 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.74 · 2022: $348 · 2023: $577 · 2024: $549 · 2025: $3,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,830 · Travel and Lodging: $1,245 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.21 |
| Travel and Lodging | $1,245.25 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,636.09 | 2025 | Inspire |
| Jazz Pharmaceuticals INC. | $544.20 | 2024-2025 | |
| Harmony Biosciences LLC | $407.68 | 2024-2025 | |
| Axsome Therapeutics, INC. | $405.97 | 2024-2025 | Sunosi |
| Lilly USA, LLC | $214.88 | 2022-2025 | Zepbound, Emgality, Mounjaro |
| Abbvie INC. | $168.22 | 2021-2025 | |
| Novo Nordisk INC | $137.39 | 2022-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $130.22 | 2022-2024 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.17 | 2022-2023 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lundbeck LLC | $85.95 | 2024 | Rexulti |
| Astellas Pharma US INC | $72.29 | 2023-2024 | Veozah |
| Merck Sharp & Dohme LLC | $65.83 | 2023-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $59.89 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $49.70 | 2022-2023 | Rexulti |
| Glaxosmithkline, LLC. | $45.14 | 2022-2023 | Shingrix, Bexsero, Trelegy Ellipta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $44.22 | 2024-2025 | Remede System |
| Exact Sciences Corporation | $37.01 | 2023 | Cologuard Collection Kit |
| Resmed Corp | $35.69 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.83 | 2023 | Caplyta |
| Pfizer INC. | $31.10 | 2022-2023 | |
| Daiichi Sankyo INC. | $28.56 | 2022-2023 | Injectafer |
| 3b Medical, INC. | $22.59 | 2025 | Luna |
| Takeda Pharmaceuticals U.S.A., INC. | $21.80 | 2022 | |
| Dexcom, INC. | $19.95 | 2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $19.05 | 2024 | Camzyos |
| Corium, LLC | $18.70 | 2022 | |
| Phadia US INC. | $17.91 | 2022 | |
| Alkermes, INC. | $17.33 | 2022 | |
| Cranial Technologies, INC | $15.38 | 2024 | Doc Band |
| Esperion Therapeutics, INC. | $14.71 | 2023 | Nexletol |
| Phathom Pharmaceuticals, INC. | $13.49 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcy Scheurer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.